Parkinson’s Disease Market to Exhibit Growth at a CAGR of 11.2% During the Study Period (2019-2032), Assesses DelveInsight

DelveInsight’s analysts estimate that the Parkinson’s disease market is expected to show positive growth, mainly attributed to increased prevalence and the anticipated launch of novel therapies during the forecast period (2023–2032). 

LAS VEGAS, May 30, 2023 /PRNewswire/ — DelveInsight’s Parkinson’s Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson’s disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Parkinson’s Disease Market Report

• As per DelveInsight analysis, the Parkinson’s disease market size in the 7MM was approximately USD 3.2 billion in 2022.
• According to the assessment done by DelveInsight, the estimated total diagnosed prevalent Parkinson’s disease cases in the 7MM were approximately 2.5 million in 2022. 
• Leading Parkinson’s disease companies such as Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicine, Intra-Cellular Therapies, Hoffmann-La Roche, Prothena Corporation, and others are developing novel Parkinson’s disease drugs that can be available in the Parkinson’s disease market in the coming years.
• The promising Parkinson’s disease therapies in the pipeline include Tavapadon, P2B001, ABBV-951 (foscarbidopa/foslevodopa), BIIB122/DNL151, Buntanetap, IPX203, NE3107, CVN424, CNM-Au8, ITI-214 (lenrispodun), Prasinezumab (RO7046015/RG7935/PRX002), and others.

Discover which therapies are expected to grab the major Parkinson’s disease market share @ Parkinson’s Disease Market Report

Parkinson’s Disease Overview

Parkinson’s disease is a degenerative ailment caused by the loss of nerve cells in the substantia nigra, a region of the brain that governs movement. The cause of Parkinson’s disease is unknown, however, it has long been hypothesized that exposure to environmental risk factors, together with a hereditary vulnerability, may be one explanation. The vast majority of instances are assumed to be sporadic, while up to 20% of persons with Parkinson’s disease also have a first-degree relative with the disease.

Parkinson’s disease is characterized by motor symptoms such as bradykinesia, stiffness, rest tremor, and postural instability. Non-motor symptoms, such as depression, cognitive impairment, pain, and autonomic disturbances, are very common and can have a significant impact on a patient’s quality of life. Currently, Parkinson’s disease is diagnosed mostly based on the symptoms listed above. There is no X-ray or blood test that can confirm the condition. Noninvasive diagnostic imaging, such as positron emission tomography (PET), can help a doctor make Parkinson’s disease diagnosis.

Parkinson’s Disease Epidemiology Segmentation

DelveInsight estimates that there were approximately 2.5 million diagnosed prevalent cases of Parkinson’s disease in the 7MM in 2022.

Parkinson’s disease has been identified as a male-dominant disease; in our analysis, the number of males suffering was higher as compared to females. In 2022, 54% of cases of Parkinson’s disease were in males, while 46% of cases were in females in the 7MM.

The Parkinson’s disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Parkinson’s Disease Diagnosed Prevalent Population
• Parkinson’s Disease Gender-specific Diagnosed Prevalent Population
• Parkinson’s Disease Age-specific Diagnosed Prevalent Population
• Parkinson’s Disease Stage-specific Diagnosed Prevalent Population

Parkinson’s Disease Treatment Market 

The Parkinson’s disease treatment landscape includes various drugs, although none have yet reversed the illness’s consequences. Levodopa is the gold standard for treating motor problems. Furthermore, it is usual for persons with Parkinson’s disease to take a combination of these medications – all at different doses and times of day – to manage symptoms. Levodopa, carbidopa-levodopa infusion (DUOPA), dopamine agonists, MAO B inhibitors (AZILECT, XADAGO), catechol o-methyltransferase (COMT) inhibitors, anticholinergics, adenosine A2a antagonists (ISTRADEFYLLINE), and amantadine (GOCOVRI, OSMOLEX ER) are some of the drugs used for Parkinson’s disease treatment. The primary goal of these drugs is to reduce motor symptoms, or symptoms that influence movement, in persons with Parkinson’s disease. Parkinson’s disease treatment is offered based on the stage of the disease, the symptoms displayed, and those who are already on medicine. Parkinson’s disease treatment can be categorized as early-stage, late-stage, and non-motor symptoms based on the aforementioned parameters.

INBRIJA (levodopa) is a levodopa dry powder formulation for oral inhalation with the INBRIJA inhaler. It is intended for persons with Parkinson’s disease who are receiving carbidopa-levodopa treatment. It does not replace daily carbidopa-levodopa medications, but it reduces “off-episodes” and alleviates motor symptoms. Dopamine’s metabolic precursor, levodopa, passes the blood-brain barrier and is likely converted to dopamine in the brain. This is assumed to be the mechanism by which levodopa alleviates Parkinson’s disease symptoms.

To know more about Parkinson’s disease treatment guidelines, visit @ Parkinson’s Disease Management 

Parkinson’s Disease Pipeline Therapies and Key Companies

• Tavapadon: Cerevel Therapeutics/Pfizer
• P2B001: Pharma Two B
• ABBV-951 (foscarbidopa/foslevodopa): AbbVie
• BIIB122/DNL151: Biogen/Denali Therapeutics
• Buntanetap: Annovis Bio
• IPX203: Amneal Pharmaceuticals
• NE3107: BioVie
• CVN424: Cerevance
• CNM-Au8: Clene Nanomedicine
• ITI-214 (lenrispodun): Intra-Cellular Therapies
• Prasinezumab (RO7046015/RG7935/PRX002): Hoffmann-La Roche/Prothena Corporation

Learn more about the FDA-approved drugs for Parkinson’s disease @ Drugs for Parkinson’s Disease Treatment 

Parkinson’s Disease Market Dynamics

The Parkinson’s disease market is anticipated to change in the coming years. Parkinson’s disease causes a significant yearly psychological, social, and economic cost (QALY) in developed countries. Growing research and development are boosting the demand for better Parkinson’s disease diagnosis and treatment alternatives. To tackle the obstacles posed by this entity, medicines with novel mechanisms of action and combinations have been researched in recent years. The development of a disease-modifying medicine has the potential to boost the Parkinson’s disease market share. 

Furthermore, the Parkinson’s disease pipeline is very robust; many potential therapies are being investigated for the treatment of Parkinson’s disease, and it is safe to predict that the treatment space will significantly impact the Parkinson’s disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Parkinson’s disease market in the 7MM.

However, several factors are impeding the growth of Parkinson’s disease market. There is no known cure for Parkinson’s disease, and the only pharmacological treatment available is symptomatic. These medications serve only to alleviate symptoms. Understanding disease processes and creating treatments becomes more difficult as disease complexity increases. The medications are hampered by specific side effects, as well as patent expiration. Many Parkinson’s disease patients go undetected since there are no confirmatory procedures. 

Furthermore, the Parkinson’s disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Parkinson’s disease market growth.

Scope of the Parkinson’s Disease Market Report

• Therapeutic Assessment: Parkinson’s Disease current marketed and emerging therapies
• Parkinson’s Disease Market Dynamics: Attribute Analysis of Emerging Parkinson’s Disease Drugs 
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Parkinson’s Disease Market Access and Reimbursement

Discover more about Parkinson’s disease drugs in development @ Parkinson’s Disease Clinical Trials

Table of Contents

Related Reports

Parkinson’s Disease Epidemiology Forecast

Parkinson’s Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Parkinson’s disease epidemiology trends.

Parkinson’s Disease Pipeline

Parkinson’s Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson’s disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others.

Psychosis in Parkinson’s and Alzheimer’s Disease Market

Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson’s and Alzheimer’s disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, among others.

Parkinson’s Disease-Related Dementia Market

Parkinson’s Disease-Related Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease-related dementia companies, including AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur 
[email protected] 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

SOURCE DelveInsight Business Research, LLP